SURMOUNT-CN

CompletedPhase 3Results posted

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)

Lead sponsor

Eli Lilly and Company

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

—

Enrollment

210

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥28

Primary endpoints

•Body weight, % change•≥5% weight-loss responders

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05024032

Org study ID17507

Secondary IDI8F-MC-GPIAEli Lilly and Company

Timeline

Milestones

Study first posted2021-08-27actual

Study start2021-09-01actual

Primary completion2022-12-27actual

Study completion2022-12-27actual

Last update posted2024-01-19actual

Results first posted2024-01-19actual

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have a BMI ≥28 kilogram/square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease

•Have a history of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

•Have Diabetes Mellitus

•Have a self-reported change in body weight >5 kg within 3 months prior to screening

•Have obesity induced by other endocrinological disorders

•Have had a history of chronic or acute pancreatitis

•Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within the last 2 years

•Have any lifetime history of a suicide attempt

•Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)

Endpoints (42)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Cardiometabolic biomarkers

Glycemic / diabetes

Patient-reported / QoL

Weight & body composition

16 endpoints

Primary/registry result

Mean Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 52

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Percent change	95% CI
10 mg Tirzepatide	-14.4	—
15 mg Tirzepatide	-19.9	—
Placebo	-2.4	—

LS Mean Difference-12.095% CI-14.8 – -9.3p<0.001Mixed Models Analysis

LS Mean Difference-17.595% CI-20.3 – -14.8p<0.001Mixed Models Analysis

Primary/registry result

Percentage of Participants Who Achieve ≥5% Body Weight Reduction

Time frame:Week 52

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
10 mg Tirzepatide	91.43	—
15 mg Tirzepatide	92.65	—
Placebo	29.41	—

Odds Ratio (OR)23.1195% CI8.80 – 60.69p<0.001Regression, Logistic

Odds Ratio (OR)26.5395% CI9.61 – 73.24p<0.001Regression, Logistic

Primary/protocol endpoint

Mean Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 52

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Percentage of Participants Who Achieve ≥5% Body Weight Reduction

Time frame:Week 52

≥5% weight-loss responders

threshold achievement, improvement

Secondary/registry result

Mean Change From Baseline in Body Weight

Time frame:Baseline, Week 20

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
10 mg Tirzepatide	-9.0	—
15 mg Tirzepatide	-11.1	—
Placebo	-1.8	—

LS Mean Difference-7.295% CI-8.8 – -5.5p<0.001Mixed Models Analysis

LS Mean Difference-9.295% CI-10.9 – -7.5p<0.001Mixed Models Analysis

Secondary/registry result

Percentage of Participants Who Achieve ≥10% Body Weight Reduction

Time frame:Week 52

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
10 mg Tirzepatide	70.0	—
15 mg Tirzepatide	83.82	—
Placebo	14.71	—

Odds Ratio (OR)13.1995% CI5.63 – 30.89p<0.001Regression, Logistic

Odds Ratio (OR)28.5895% CI11.23 – 72.71p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥15% Body Weight Reduction

Time frame:Week 52

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), Percentage of participants	95% CI
10 mg Tirzepatide	48.57	—
15 mg Tirzepatide	72.06	—
Placebo	2.94	—

Odds Ratio (OR)25.6495% CI6.68 – 98.49p<0.001Regression, Logistic

Odds Ratio (OR)69.7995% CI17.69 – 275.37p<0.001Regression, Logistic

Secondary/registry result

Mean Change From Baseline in Waist Circumference

Time frame:Baseline, Week 52

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), centimeters (cm)	95% CI
10 mg Tirzepatide	-11.9	—
15 mg Tirzepatide	-16.4	—
Placebo	-2.7	—

LS Mean Difference-9.295% CI-11.5 – -6.9p<0.001Mixed Models Analysis

LS Mean Difference-13.795% CI-16.0 – -11.3p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Absolute Body Weight

Time frame:Baseline, Week 52

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
10 mg Tirzepatide	-13.1	—
15 mg Tirzepatide	-18.1	—
Placebo	-2.1	—

LS Mean Difference-10.995% CI-13.5 – -8.3p<0.001Mixed Models Analysis

LS Mean Difference-16.095% CI-18.6 – -13.4p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 52

BMI, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms per metres squared (kg/m^2)	95% CI
10 mg Tirzepatide	-4.7	—
15 mg Tirzepatide	-6.4	—
Placebo	-0.8	—

LS Mean Difference-3.995% CI-4.8 – -3.1p<0.001Mixed Models Analysis

LS Mean Difference-5.695% CI-6.4 – -4.8p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Mean Change From Baseline in Body Weight

Time frame:Baseline, Week 20

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥10% Body Weight Reduction

Time frame:Week 52

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥15% Body Weight Reduction

Time frame:Week 52

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Waist Circumference

Time frame:Baseline, Week 52

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Absolute Body Weight

Time frame:Baseline, Week 52

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 52

BMI, change

change from baseline, improvement

Glycemic / diabetes

6 endpoints

Secondary/registry result

Mean Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 52

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), Percentage of HbA1c	95% CI
10 mg Tirzepatide	-0.34	—
15 mg Tirzepatide	-0.35	—
Placebo	0.03	—

LS Mean Difference-0.3795% CI-0.46 – -0.28p<0.001Mixed Models Analysis

LS Mean Difference-0.3995% CI-0.48 – -0.29p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Fasting Glucose (FSG)

Time frame:Baseline, Week 52

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), millimoles per liter (mmol/L)	95% CI
10 mg Tirzepatide	-0.25	—
15 mg Tirzepatide	-0.33	—
Placebo	0.22	—

LS Mean Difference-0.4695% CI-0.61 – -0.32p<0.001Mixed Models Analysis

LS Mean Difference-0.5495% CI-0.69 – -0.40p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), milliunits per liter (mU/L)	95% CI
Tirzepatide Pooled Analysis	-6.5	—
Placebo	-0.2	—

LS Mean Difference-6.395% CI-8.6 – -4.0

Secondary/protocol endpoint

Mean Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 52

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Mean Change From Baseline in Fasting Glucose (FSG)

Time frame:Baseline, Week 52

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

change from baseline, improvement

Cardiometabolic biomarkers

16 endpoints

Secondary/registry result

Mean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Value (least_squares_mean), millimeters of Mercury (mmHg)	95% CI
Tirzepatide Pooled Analysis	-6.1	—
Placebo	-1.3	—

LS Mean Difference-4.895% CI-6.9 – -2.7p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (least_squares_mean), millimeters of Mercury (mmHg)	95% CI
Tirzepatide Pooled Analysis	-9.6	—
Placebo	-3.5	—

LS Mean Difference-6.195% CI-9.1 – -3.1p<0.001Mixed Models Analysis

Secondary/registry result

Mean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Posted result

Group	Value (least_squares_mean), millimoles per liter (mmol/L)	95% CI
Tirzepatide Pooled Analysis	-0.37	—
Placebo	-0.06	—

LS Mean Difference-0.3195% CI-0.51 – -0.11

Secondary/registry result

Mean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Posted result

Group	Value (least_squares_mean), millimoles per liter (mmol/L)	95% CI
Tirzepatide Pooled Analysis	0.12	—
Placebo	0.03	—

LS Mean Difference0.0995% CI0.03 – 0.14

Secondary/registry result

Mean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Posted result

Group	Value (least_squares_mean), millimoles per liter (mmol/L)	95% CI
Tirzepatide Pooled Analysis	-0.17	—
Placebo	-0.11	—

LS Mean Difference-0.0695% CI-0.25 – 0.13

Secondary/registry result

Mean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

VLDL, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), millimoles per liter (mmol/L)	95% CI
Tirzepatide Pooled Analysis	-0.28	—
Placebo	-0.03	—

LS Mean Difference-0.2595% CI-0.34 – -0.16

Secondary/registry result

Mean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Posted result

Group	Value (least_squares_mean), millimoles per liter (mmol/L)	95% CI
Tirzepatide Pooled Analysis	-0.63	—
Placebo	-0.05	—

LS Mean Difference-0.5895% CI-0.79 – -0.37

Secondary/registry result

Mean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Free fatty acids, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), millimoles per liter (mmol/L)	95% CI
Tirzepatide Pooled Analysis	-0.16	—
Placebo	-0.10	—

LS Mean Difference-0.0795% CI-0.12 – -0.01

Secondary/protocol endpoint

Mean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Mean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Mean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Mean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Mean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Mean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

VLDL, change

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Mean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 52

Free fatty acids, change

change from baseline, improvement

Patient-reported / QoL

4 endpoints

Secondary/registry result

Mean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

Time frame:Baseline, Week 52

SF-36 physical

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Score on a scale	95% CI
10 mg Tirzepatide	2.0	—
15 mg Tirzepatide	1.9	—
Placebo	0.8	—

LS Mean Difference1.295% CI0.0 – 2.3p0.044ANCOVA

LS Mean Difference1.295% CI0.0 – 2.3p0.050ANCOVA

Secondary/registry result

Mean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

Time frame:Baseline, Week 52

IWQOL-Lite physical

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), Score on a scale	95% CI
10 mg Tirzepatide	11.2	—
15 mg Tirzepatide	12.0	—
Placebo	3.5	—

LS Mean Difference7.895% CI3.7 – 11.8p<0.001ANCOVA

LS Mean Difference8.595% CI4.4 – 12.7p<0.001ANCOVA

Secondary/protocol endpoint

Mean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

Time frame:Baseline, Week 52

SF-36 physical

change from baseline, improvement

Secondary/protocol endpoint

Mean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

Time frame:Baseline, Week 52

IWQOL-Lite physical

change from baseline, improvement

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Achieving BMI <25 kg/m(2) was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN.
EClinicalMedicine2026 Jan (month)PMID41536939doi:10.1016/j.eclinm.2025.103722via pubmed nct search
Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial.
Life metabolism2025 Oct (month)PMID42058132doi:10.1093/lifemeta/loaf024via pubmed nct search
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
JAMA2024 Aug 20PMID38819983doi:10.1001/jama.2024.9217via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.